English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Friday, September 30, 2016
Eisai to Initiate Phase III Clinical Study of Anti-Cancer Agent Lenvatinib as Potential First-Line Therapy for Advanced Renal Cell Carcinoma
エーザイ、抗がん剤「レンバチニブ」の進行性腎細胞がん一次治療対象の臨床第III相試験を開始
Thursday, September 29, 2016
Eisai to Present Latest Data on Lenvatinib and Eribulin at ESMO Congress 2016
Wednesday, September 28, 2016
AbbVie and Eisai Obtain Additional Approval for New Indication of Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA in the Treatment of non-infectious Uveitis
Eisai Commences Provision of "EMILY" Smartphone App to Support Living with Epilepsy in Japan
Eisai Submits Supplemental Application for Partial Label Change for Antiepileptic Drug Fycompa
Tuesday, September 27, 2016
エーザイ、抗てんかん剤「Fycompa」 部分てんかんの単剤療法での使用に関する一部変更申請を米国FDAの新ポリシーに基づいて提出
Thursday, September 15, 2016
Eisai Receives License for New Indication for Anticancer Agent Kisplyx (Lenvatinib Mesylate) for Treatment of Advanced Renal Cell Carcinoma
エーザイ、抗がん剤「Kisplyx」が欧州において新たに進行性腎細胞がんに関する適応の承認を取得
Wednesday, September 14, 2016
エーザイ、社会的責任投資指数「Dow Jones Sustainability Asia Pacific Index」に4年連続選定

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575